Valneva (NASDAQ:VALN – Get Free Report) and Sharps Technology (NASDAQ:STSS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.
Profitability
This table compares Valneva and Sharps Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valneva | -57.81% | -59.44% | -21.65% |
| Sharps Technology | N/A | -84.26% | -79.52% |
Volatility & Risk
Valneva has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valneva | 1 | 0 | 3 | 0 | 2.50 |
| Sharps Technology | 1 | 0 | 0 | 0 | 1.00 |
Valneva currently has a consensus price target of $15.00, suggesting a potential upside of 35.01%. Given Valneva’s stronger consensus rating and higher probable upside, research analysts clearly believe Valneva is more favorable than Sharps Technology.
Institutional & Insider Ownership
11.4% of Valneva shares are held by institutional investors. Comparatively, 17.2% of Sharps Technology shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 1.2% of Sharps Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Valneva and Sharps Technology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valneva | $183.52 million | 5.21 | -$13.25 million | ($1.44) | -7.72 |
| Sharps Technology | N/A | N/A | -$9.30 million | ($831.83) | 0.00 |
Sharps Technology has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.
Summary
Valneva beats Sharps Technology on 8 of the 13 factors compared between the two stocks.
About Valneva
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
